Guided by "cooperation with pharmaceutical distribution to promote internationalization". The company's seven pharmaceutical companies, including Sinopharm Yixin Pharmaceutical Co., Ltd., Shenzhen Zhijun Pharmaceutical Co., Ltd., Sinopharm Guo Rui Pharmaceutical Co., Ltd., Suzhou Zhijun Wanqing Pharmaceutical Co., Ltd., Sinopharm Xingsha Pharmaceutical (Xiamen) Co., Ltd., Sinopharm Shenzhen Chinese Medicine Co., Ltd. and Sinopharm Lerentang Hebei Pharmaceutical Co., Ltd., which mainly produce antibiotics, antineoplastic drugs, cardiovascular and cerebrovascular drugs, cough drugs and proprietary Chinese medicines, are constantly introducing world-class technologies to build a modern industrial platform with characteristics.
Sinopharm Chemical Reagent Co., Ltd., which belongs to the company, is the largest chemical reagent business enterprise in China. The product application field covers scientific research institutes and universities, and is applied to biotechnology, environmental testing, drug research and development, quality testing, educational experiments and many other aspects. It has branches and subsidiaries in Shanghai, Beijing, Shenyang, Xi 'an, Suzhou, Chengdu, Taicang and other regions, and has a number of well-known independent brands and independent import and export rights such as Wokai, SCRC, Shanghai Test, Beijing Test and Shenbo.
Sinopharm Holding Medical Devices Co., Ltd. under the company is a professional medical device enterprise integrating product sales agency, distribution, chain operation and after-sales service. The company will take Sinopharm Holding Medical Devices Co., Ltd. as a platform to further expand the upstream and downstream of the industrial value chain and build a "medical device management enterprise with the widest domestic coverage network, the most modern distribution service level and international competitiveness".
Yu Jia Medical Service Co., Ltd., a subsidiary of our company, focuses on the expansion of medical services. By investing in the acquisition and development of self-operated or re-targeted single-department chain hospitals, we are committed to expanding the complete pharmaceutical industry chain with added value, realizing the penetration of the value chain of state-controlled health industry, and accelerating the transformation of state-controlled health industry from pharmaceutical product distributors to health industry service providers.